Dobutamine

Mechanism

Mechanism of Action

Synthetic drug administered as a racemic mixture. The (-) isomer is a potent agonist of the α₁ adrenergic receptor, while the (+) isomer is a potent antagonist of this receptor and a very effective agonist of the β₁ and β₂ receptors. Clinically, the resulting net effect is a predominant and selective stimulation of myocardial β₁ receptors, significantly increasing inotropism and dromotropism with a minor chronotropic effect compared to the purified isomer. The slight concomitant stimulation of β₂ receptors compensates for the α₁ effect, producing a modest peripheral vasodilation that reduces ventricular afterload, optimizing global cardiac output.

Pharmacokinetics

Key Pharmacokinetics

• Routes: Continuous intravenous infusion only parenterally.
• Metabolism: Hepatic through conjugation by methylation by COMT to an inactive metabolite (3-O-methyldobutamine).
• Half-life: Extremely short, approximately 2 minutes.
• Excretion: Renal, eliminating the glucuronide conjugates almost completely in the 24 hours following the start of treatment.

Indicators and dose

Approved and Off-label Indications

Approved: Acute decompensated congestive heart failure, cardiogenic shock (often associated with a vasopressor such as norepinephrine), pharmacological stress echocardiography in patients unable to perform physical exercise.

Off-label: Transient hemodynamic support during ventilation with elevated positive end-expiratory pressure (PEEP).

Dosage and Adjustments

Continuous Infusion: Usual dosage range of 2.5 to 20 µ g/kg/min IV, individually adjusted according to hemodynamic and clinical parameters. Doses greater than 20 µ g/kg/min increase the risk of arrhythmias.

Renal/hepatic adjustment: No specific dose adjustments are required in renal or hepatic insufficiency given its rapid peripheral enzymatic degradation.

Security

Contraindications

Absolute: Idiopathic dynamic hypertrophic subaortic stenosis (hypertrophic obstructive cardiomyopathy), proven hypersensitivity to the active ingredient or sulfites.

Relative: Severe aortic stenosis of calcific etiology, atrial fibrillation with rapid uncontrolled ventricular response.

Adverse Effects (ADR)

Common: Moderate increase in heart rate (5-15 bpm) and systolic blood pressure, ventricular extrasystoles, referred palpitations, postinfusion nausea.

Serious: Malignant ventricular arrhythmias (including polymorphic ventricular tachycardia), silent or symptomatic myocardial ischemia due to a critical increase in tissue oxygen demand, moderate hypokalemia due to intracellular redistribution mediated by β₂ receptors.

Interactions

β adrenergic blockers: They directly antagonize the positive inotropic effects of dobutamine, and the α₁ vasoconstrictor effect of the (-) isomer may predominate.

Halogenated inhaled anesthetics: High risk of ventricular arrhythmias due to myocardial electrical sensitization.

Pregnancy and Breastfeeding

FDA Classification: Category B. No defined teratogenic effects have been observed in animal models. It is advisable to temporarily suspend breast-feeding during the active infusion period.